Charles River Laboratories International, Inc.
CRL
$175.92
$6.653.93%
| Weiss Ratings | CRL - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | D+ | |||
| Rating Factors | CRL - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Fair | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | CRL - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.96 | |||
| Price History | CRL - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 4.74% | |||
| 30-Day Total Return | 5.43% | |||
| 60-Day Total Return | -8.28% | |||
| 90-Day Total Return | -3.73% | |||
| Year to Date Total Return | -3.68% | |||
| 1-Year Total Return | -34.91% | |||
| 2-Year Total Return | -20.44% | |||
| 3-Year Total Return | -33.98% | |||
| 5-Year Total Return | 23.18% | |||
| 52-Week High % Change | -38.45% | |||
| 52-Week Low % Change | 12.26% | |||
| Price | CRL - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $275.00 | |||
| 52-Week Low Price | $150.79 | |||
| 52-Week Low Price (Date) | Feb 12, 2025 | |||
| 52-Week High Price (Date) | Mar 08, 2024 | |||
| Valuation | CRL - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 8.66B | |||
| Enterprise Value | 11.29B | |||
| Price/Earnings (TTM) | 1,115.82 | |||
| Earnings Per Share (TTM) | 0.15 | |||
| Earnings Per Share Growth | -98.35% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 2.14 | |||
| Price/Book (Q) | 2.50 | |||
| Enterprise Value/Revenue (TTM) | 2.79 | |||
| Price | $175.92 | |||
| Enterprise Value/EBITDA (TTM) | 12.65 | |||
| Enterprise Value/EBIT | 20.91 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | CRL - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 51.14M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CRL - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 781 222 6000 | |||
| Address | 251 Ballardvale Street Wilmington, MA 01887 | |||
| Website | www.criver.com | |||
| Country | United States | |||
| Year Founded | 1947 | |||
| Profitability | CRL - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 13.33% | |||
| Profit Margin | 0.54% | |||
| Management Effectiveness | CRL - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 4.29% | |||
| Return on Equity | 0.71% | |||
| Income Statement | CRL - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 4.05B | |||
| Total Revenue (TTM) | 4.05B | |||
| Revenue Per Share | $79.20 | |||
| Gross Profit (TTM) | 1.40B | |||
| EBITDA (TTM) | 892.30M | |||
| EBIT (TTM) | 539.96M | |||
| Net Income (TTM) | 22.20M | |||
| Net Income Avl. to Common (TTM) | 22.20M | |||
| Total Revenue Growth (Q YOY) | -1.08% | |||
| Earnings Growth (Q YOY) | -213.12% | |||
| EPS Diluted (TTM) | 0.15 | |||
| EPS Diluted Growth (Q YOY) | -216.41% | |||
| Balance Sheet | CRL - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 194.61M | |||
| Cash Per Share (Q) | $3.81 | |||
| Total Current Assets (Q) | 1.40B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 3.51B | |||
| Current Ratio (Q) | 1.411 | |||
| Book Value Per Share (Q) | $67.69 | |||
| Total Assets (Q) | 7.53B | |||
| Total Current Liabilities (Q) | 994.10M | |||
| Total Debt (Q) | 2.78B | |||
| Total Liabilities (Q) | 4.02B | |||
| Total Common Equity (Q) | 3.46B | |||
| Cash Flow | CRL - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -245.09M | |||
| Cash from Financing (TTM) | -550.93M | |||
| Net Change in Cash (TTM) | -78.91M | |||
| Levered Free Cash Flow (TTM) | 494.31M | |||
| Cash from Operations (TTM) | 734.58M | |||
